CH512505A - Anti-inflammatory analgesic antipyretic oxazole - Google Patents
Anti-inflammatory analgesic antipyretic oxazoleInfo
- Publication number
- CH512505A CH512505A CH83871A CH83871A CH512505A CH 512505 A CH512505 A CH 512505A CH 83871 A CH83871 A CH 83871A CH 83871 A CH83871 A CH 83871A CH 512505 A CH512505 A CH 512505A
- Authority
- CH
- Switzerland
- Prior art keywords
- parts
- salts
- oxazole
- chlorophenyl
- water
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 3
- 230000001754 anti-pyretic effect Effects 0.000 title abstract description 3
- 239000002221 antipyretic Substances 0.000 title abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- -1 phenyl- Chemical group 0.000 claims abstract description 10
- 150000007978 oxazole derivatives Chemical class 0.000 claims abstract description 6
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 8
- 239000007787 solid Substances 0.000 abstract description 3
- JTTKIXKOKLCMST-UHFFFAOYSA-N 2-(1,3-oxazol-4-yl)acetic acid Chemical compound OC(=O)CC1=COC=N1 JTTKIXKOKLCMST-UHFFFAOYSA-N 0.000 abstract description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000004411 aluminium Substances 0.000 abstract 1
- 239000005457 ice water Substances 0.000 abstract 1
- 235000011149 sulphuric acid Nutrition 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- KUNURROGBCFQQW-UHFFFAOYSA-N 4-(4-bromophenyl)-2-methyl-1,3-oxazole Chemical compound O1C(C)=NC(C=2C=CC(Br)=CC=2)=C1 KUNURROGBCFQQW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- MCSIVMBXRSMJAI-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-1,3-oxazol-4-yl]acetic acid Chemical compound OC(=O)CC1=COC(C=2C=CC(Cl)=CC=2)=N1 MCSIVMBXRSMJAI-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- QEBSBPCGSJGODT-UHFFFAOYSA-N 2-(4-phenyl-1,3-oxazol-2-yl)acetic acid Chemical compound O1C(CC(=O)O)=NC(C=2C=CC=CC=2)=C1 QEBSBPCGSJGODT-UHFFFAOYSA-N 0.000 description 1
- XVSRQHPNIFGWJJ-UHFFFAOYSA-N 2-[2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]acetic acid Chemical compound OC(=O)CC1=COC(C=2C=CC(=CC=2)C(F)(F)F)=N1 XVSRQHPNIFGWJJ-UHFFFAOYSA-N 0.000 description 1
- ZRMWWPACEXVUTK-UHFFFAOYSA-N 2-[4-(4-bromophenyl)-1,3-oxazol-2-yl]acetic acid Chemical compound O1C(CC(=O)O)=NC(C=2C=CC(Br)=CC=2)=C1 ZRMWWPACEXVUTK-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- FGTSBVMVXJRFBS-UHFFFAOYSA-N 2-methyl-4-phenyl-1,3-oxazole Chemical compound O1C(C)=NC(C=2C=CC=CC=2)=C1 FGTSBVMVXJRFBS-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- NRESPXCAXZVCOX-UHFFFAOYSA-N C1(=CC=CC=C1)C=1N=C(OC1)C(C(=O)OCC)(C(=O)OCC)C Chemical compound C1(=CC=CC=C1)C=1N=C(OC1)C(C(=O)OCC)(C(=O)OCC)C NRESPXCAXZVCOX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- UZLOZDPULGKABX-UHFFFAOYSA-N diethyl 2-(4-phenyl-1,3-oxazol-2-yl)propanedioate Chemical compound C1(=CC=CC=C1)C=1N=C(OC1)C(C(=O)OCC)C(=O)OCC UZLOZDPULGKABX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23F—NON-MECHANICAL REMOVAL OF METALLIC MATERIAL FROM SURFACE; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL; MULTI-STEP PROCESSES FOR SURFACE TREATMENT OF METALLIC MATERIAL INVOLVING AT LEAST ONE PROCESS PROVIDED FOR IN CLASS C23 AND AT LEAST ONE PROCESS COVERED BY SUBCLASS C21D OR C22F OR CLASS C25
- C23F11/00—Inhibiting corrosion of metallic material by applying inhibitors to the surface in danger of corrosion or adding them to the corrosive agent
- C23F11/04—Inhibiting corrosion of metallic material by applying inhibitors to the surface in danger of corrosion or adding them to the corrosive agent in markedly acid liquids
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23G—CLEANING OR DE-GREASING OF METALLIC MATERIAL BY CHEMICAL METHODS OTHER THAN ELECTROLYSIS
- C23G1/00—Cleaning or pickling metallic material with solutions or molten salts
- C23G1/02—Cleaning or pickling metallic material with solutions or molten salts with acid solutions
- C23G1/04—Cleaning or pickling metallic material with solutions or molten salts with acid solutions using inhibitors
- C23G1/06—Cleaning or pickling metallic material with solutions or molten salts with acid solutions using inhibitors organic inhibitors
- C23G1/068—Cleaning or pickling metallic material with solutions or molten salts with acid solutions using inhibitors organic inhibitors compounds containing a C=C bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Metallurgy (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Oxazole derivatives - (I) Y = phenyl-, benzyl- which may be subst. by up to 2 hal- or CF3 - Z = -CR1R2R3 - R1 = H-, C1-3 alkyl- - R2 = H-, C1-3 alkyl-, C2-6 alkoxycarbonyl- - R3 = CO2R4 or -CONHR5 - R4 = H-, alkyl-, dialkylaminoalkyl-, benzyl-, phenyl-, R5 = H-, -OH, -NH2, dialkylaminoalkyl-, alkoxycarbonylalkyl-, carboxyalkyl-particularly aluminium 2-(4-chlorophenyl) oxazol-4-acetate. - Anti-inflammatory, analgesic, antipyretic. - A mixture of 2(4-chlorophenyl)-4-cyanomethyl-oxazole, dry ethanol and conc. H2SO4 is heated for 10 hours at 100 deg.C. The solution is poured into ice-water and the mixture filtered to yield solid ethyl 2-(4-chlorophenyl)oxazol-4-yl acetate.
Description
Verfahren zur Herstellung von Oxazolderivaten Die Erfindung betrifft ein Verfahren zur Herstellung neuer Oxazolderivate mit. entzündungsverhindernden, schmerzstillenden und antipyretischen Eigenschaften.
Gemäss der Erfindung werden Oxazolderivate der Formel:
EMI0001.0000
und deren Salze hergestellt, wobei Y einen Phenyl- oder Benzylrest, die im Benzolring gegebenenfalls durch ein oder zwei Halogenatome oder den Trifluormethylrest sub stituiert sein können, und R' ein Wasserstoffatom oder einen Alkylrest mit höchstens 3 C-Atomen bedeuten.
Der Oxazolkern wird wie folgt numeriert:
EMI0001.0001
Es ist aus der obigen Formel ohne weiteres ersichtlich, dass die Gruppe -CHR'-COOH in der 4-Stellung steht, wenn Y in der 2-Stellung steht, und in der 2-Stellung, wenn Y in der 4-Stellung steht.
Die in Y gegebenenfalls vorhandenen Substituenten können z. B. aus Fluor-, Chlor- und Bromatomen gewählt werden. Stellt R' ein Alkylradikal mit höchstens 3 C-Ato- men dar, so kann dieses z. B. das Methylradikal sein.
Als Beispiele von Salzen seien solche mit Alkalimetal len oder Erdalkalimetallen, oder Aluminium- oder Ammo niumsalze oder Salze mit organischen Basen, die nichtgif tige, pharmazeutisch zulässige Kationen geben, angeführt.
Die nach dem erfindungsgemässen Verfahren erhältli chen, bevorzugten Oxazolderivate sind: 2-(4-Chlorphenyl) oxazol-4-ylessigsäure, α-12-(4-Chlorphenyl)-oxazol-4-yllpro- pionsäure, 2-(4-Trifluormethylphenyl)-oxazol-4-ylessigsäure und 244-Bromphenyl)oxazol-4-ylessigsäure sowie die Alka limetall-, Erdalkalimetall- und Aluminiumsalze davon.
Das erfindungsgemässe Verfahren ist dadurch gekenn zeichnet, dass man eine Verbindung der Formel
EMI0001.0006
in welcher Y und R' obige Bedeutung besitzen und R2 für einen Alkylrest steht, mit einer anorganischen Base in Ge genwart von Wasser und in der Wärme behandelt.
Bei dieser Reaktion erfolgt natürlich sowohl eine Hy drolyse als auch eine Decarboxylierung. Als Base eignet sich z. B. ein Alkalimetallhydroxyd.
Beispiel l Eine Mischung von 1 Teil 2-Methyl-4-phenyl-oxazol, 0,75 Teil Natriumhydrid und 10 Teilen Diäthylcarbonat wird 4 Stunden unter Rückfluss gekocht. Die Mischung wird abgekühlt, in 10 Teile Wasser gegossen und mit 2n-Salzsäure angesäuert. Die Mischung wird 2mal mit Äther extrahiert. Die vereinigten ätherischen Extrakte werden mit Wasser gewaschen und dann an wasserfreiem Natriumsulfat getrocknet, filtriert und im Vakuum zur Trockne eingedampft. Der Rückstand besteht aus Diäthyl- 2-(4-phenyloxazol-2-yl)malonat.
Diese Verbindung wird zusammen mit 30 Teilen 2n-Na- triumhydroxyd 1 Stunde unter Rückfluss erhitzt. Die Mi schung wird abgekühlt und mit 10 Teilen Äther gewa schen. Die wässrige Schicht wird abgetrennt und mit 2n-Salzsäure bei 0 C angesäuert. Der entstehende Nieder schlag wird abfiltriert und mit Wasser und dann mit Ätha- nol gewaschen. Somit erhält man 4-Phenyloxazol-2-ylessig- säure, Smp. 132 C unter Zersetzung.
Auf im wesentlichen gleiche Weise erhält man aus 4-(4-Brompheny@)-2-methyloxazol Diäthyl-4-(4-bromphenyl) oxazol-2-ylmalonat und 4-(4-Bromphenyl)oxazol-2-ylessig- säure, Smp. 111-112 C unter Zersetzung.
Das als Ausgangsstoff verwendete 4-(4-Bromphenyl)-2- methyloxazol kann wie folgt dargestellt werden: Es werden 25 Teile Acetamid auf 120 C erhitzt, und 70 Teile 4-Bromphenacyl-bromid werden anteilweise wäh rend 1 Stunde unter gründlichem Rühren hinzugegeben. Nach weiteren 90 Minuten bei 120-140 C wird die Mi schung abgekühlt, worauf 150 Teile Wasser und 150 Teile Chloroform hinzugegeben werden. Das Gemisch wird ge schüttelt und dann getrennt, worauf die Chloroform- Schicht im Vakuum zur Trockne eingedampft wird. Der feste Rückstand wird aus 50 vol.-%igem wässrigem Ätha- nol umkristallisiert.
Somit erhält man 4-(4-Bromphenyl)-2- methyloxazol, Smp. 98-99 C.
Beispiel 2 Es werden 30 Teile trockenen Dimethylformamids zu 2 Teilen einer 50%igen Dispersion von Natriumhydrid in <B>Öl</B> zugegeben. Dann werden diesem Gemisch 6 Teile Diäthyl-4-phenyloxazol-2-ylmalonat (siehe Beispiel 1) in 30 Teilen trockenen Dimethylformamids zugegeben. Das Gemisch wird 1 Stunde gerührt, worauf 6 Teile Methyljo- did während 10 Minuten hinzugegeben werden. Das Ge misch wird dann noch 2 Stunden gerührt. Dann wird dass Gemisch in 100 Teile Wasser und 6 Teile Essigsäure und 100 Teile Äther eingegossen. Die ätherische Schicht wird abgetrennt und mit überschüssigem wässrigem Natriumbi- carbonat gewaschen. Der Äther wird in Vakuum abge dampft.
Man erhält rohes Diäthyl-(4-phenyloxazol-2-yl)-2- methylmalonat.
Dieses Diäthylderivat wird mit 2 Teilen Natriumhydro xyd, 15 Teilen Wasser und 15 Teilen Äthanol vermischt und die Mischung 1 Stunde unter Rückfluss erhitzt. Die Mischung wird dann abgekühlt, mit 30 Teilen Wasser ver dünnt und mit 30 Teilen Äther gewaschen. Die wässrige Schicht wird auf 0 C gekühlt und mit konzentrierter Salz säure angesäuert. Das entstehende Gemisch wird filtriert. Somit erhält man als festen Rückstand (4-Phenyloxazol-2- yl)-2-propionsäure von Smp. 126-127 (Zers.).
Beispiel 3 Es wird 1 Teil 2-(4-Chlorphenyl)oxazol-4-ylessigsäure in 20 Teilen heissen 5%igen wässrigen Ammoniumhydroxyds gelöst, worauf 5 Teile 10n-Natriumhydroxyd zugegeben werden. Die Mischung wird abgekühlt und der Nieder schlag abfiltriert und aus Wasser umkristallisiert. Somit er hält man Natrium-2-(4-chlorphenyl)oxazo1-4-ylacetat von Smp. über 200 C.
Es werden 2,6 Teile Natrium-2-(4-chlorphenyl)-oxazol-4- ylacetat in 30 Teilen siedendem Wasser gelöst, worauf 2 Teile Calciumchlorid in 20 Teilen Wasser zugegeben wer den. Der Niederschlag wird abfiltriert, mit Wasser gewa schen und getrocknet. Somit erhält man Calcium-2-(4- chlorphenyl)oxazol-4-ylacetat.
Es werden 2,6 Teile Natrium-2-(4-chlorphenyl)-oxazol-4- ylacetat in 30 Teilen siedendem Wasser gelöst, worauf eine Lösung von 2 Teilen Aluminiumnitrat in 20 Teilen Wasser zugegeben wird. Nach dem Abkühlen wird der Niederschlag abfiltriert, mit Wasser gewaschen und ge trocknet. Somit erhält man Aluminium-2-(4-chlorphenyl)- oxazol-4-ylacetat.
Process for the production of oxazole derivatives The invention relates to a process for the production of new oxazole derivatives. anti-inflammatory, analgesic and antipyretic properties.
According to the invention, oxazole derivatives of the formula:
EMI0001.0000
and their salts prepared, where Y is a phenyl or benzyl radical, which may optionally be substituted in the benzene ring by one or two halogen atoms or the trifluoromethyl radical, and R 'is a hydrogen atom or an alkyl radical having at most 3 carbon atoms.
The oxazole nucleus is numbered as follows:
EMI0001.0001
It is readily apparent from the above formula that the group -CHR'-COOH is in the 4-position when Y is in the 2-position and in the 2-position when Y is in the 4-position.
The substituents optionally present in Y can, for. B. can be selected from fluorine, chlorine and bromine atoms. If R 'represents an alkyl radical with a maximum of 3 carbon atoms, this can be B. be the methyl radical.
Examples of salts are those with alkali metals or alkaline earth metals, or aluminum or ammonium salts or salts with organic bases which give non-toxic, pharmaceutically acceptable cations.
The preferred oxazole derivatives obtainable by the process according to the invention are: 2- (4-chlorophenyl) oxazol-4-ylacetic acid, α-12- (4-chlorophenyl) -oxazol-4-yl propionic acid, 2- (4-trifluoromethylphenyl ) -oxazol-4-ylacetic acid and 244-bromophenyl) oxazol-4-ylacetic acid and the alkali metal, alkaline earth metal and aluminum salts thereof.
The inventive method is characterized in that a compound of the formula
EMI0001.0006
in which Y and R 'have the above meaning and R2 stands for an alkyl radical, treated with an inorganic base in the presence of water and in the heat.
In this reaction, of course, both hydrolysis and decarboxylation occur. A suitable base is e.g. B. an alkali metal hydroxide.
Example 1 A mixture of 1 part 2-methyl-4-phenyl-oxazole, 0.75 part sodium hydride and 10 parts diethyl carbonate is refluxed for 4 hours. The mixture is cooled, poured into 10 parts of water and acidified with 2N hydrochloric acid. The mixture is extracted twice with ether. The combined ethereal extracts are washed with water and then dried over anhydrous sodium sulfate, filtered and evaporated to dryness in vacuo. The residue consists of diethyl 2- (4-phenyloxazol-2-yl) malonate.
This compound is refluxed for 1 hour together with 30 parts of 2N sodium hydroxide. The mixture is cooled and washed with 10 parts of ether. The aqueous layer is separated off and acidified with 2N hydrochloric acid at 0 C. The resulting precipitate is filtered off and washed with water and then with ethanol. This gives 4-phenyloxazol-2-ylacetic acid, melting point 132 ° C. with decomposition.
In essentially the same way, 4- (4-bromophenyl) -2-methyloxazole gives diethyl 4- (4-bromophenyl) oxazol-2-ylmalonate and 4- (4-bromophenyl) oxazol-2-ylacetic acid, M.p. 111-112 C with decomposition.
The 4- (4-bromophenyl) -2-methyloxazole used as starting material can be represented as follows: 25 parts of acetamide are heated to 120 ° C., and 70 parts of 4-bromophenacyl bromide are added in part over the course of 1 hour with thorough stirring. After a further 90 minutes at 120-140 C, the mixture is cooled, whereupon 150 parts of water and 150 parts of chloroform are added. The mixture is shaken and then separated and the chloroform layer is evaporated to dryness in vacuo. The solid residue is recrystallized from 50% strength by volume aqueous ethanol.
This gives 4- (4-bromophenyl) -2-methyloxazole, m.p. 98-99 C.
Example 2 30 parts of dry dimethylformamide are added to 2 parts of a 50% strength dispersion of sodium hydride in oil. Then 6 parts of diethyl 4-phenyloxazol-2-ylmalonate (see Example 1) in 30 parts of dry dimethylformamide are added to this mixture. The mixture is stirred for 1 hour, after which 6 parts of methyljo- did are added over 10 minutes. The mixture is then stirred for a further 2 hours. Then the mixture is poured into 100 parts of water and 6 parts of acetic acid and 100 parts of ether. The ethereal layer is separated and washed with excess aqueous sodium bicarbonate. The ether is evaporated in a vacuum.
Crude diethyl (4-phenyloxazol-2-yl) -2-methylmalonate is obtained.
This diethyl derivative is mixed with 2 parts of sodium hydroxide, 15 parts of water and 15 parts of ethanol and the mixture is refluxed for 1 hour. The mixture is then cooled, diluted with 30 parts of water and washed with 30 parts of ether. The aqueous layer is cooled to 0 C and acidified with concentrated hydrochloric acid. The resulting mixture is filtered. The solid residue thus obtained is (4-phenyloxazol-2-yl) -2-propionic acid with a melting point of 126-127 (decomp.).
Example 3 1 part of 2- (4-chlorophenyl) oxazol-4-ylacetic acid is dissolved in 20 parts of hot 5% strength aqueous ammonium hydroxide, whereupon 5 parts of 10N sodium hydroxide are added. The mixture is cooled and the precipitate is filtered off and recrystallized from water. Thus he holds sodium 2- (4-chlorophenyl) oxazo1-4-ylacetate of melting point over 200 C.
2.6 parts of sodium 2- (4-chlorophenyl) oxazol-4-ylacetate are dissolved in 30 parts of boiling water, whereupon 2 parts of calcium chloride in 20 parts of water are added. The precipitate is filtered off, washed with water and dried. Calcium 2- (4-chlorophenyl) oxazol-4-ylacetate is thus obtained.
2.6 parts of sodium 2- (4-chlorophenyl) oxazol-4-ylacetate are dissolved in 30 parts of boiling water, whereupon a solution of 2 parts of aluminum nitrate in 20 parts of water is added. After cooling, the precipitate is filtered off, washed with water and dried. Aluminum 2- (4-chlorophenyl) oxazol-4-ylacetate is thus obtained.
Claims (1)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US504056A US3401120A (en) | 1965-10-23 | 1965-10-23 | Corrosion inhibitors |
| GB4378666A GB1139940A (en) | 1966-09-30 | 1966-09-30 | Oxazole derivatives |
| CH1361967A CH507974A (en) | 1965-10-23 | 1967-09-29 | Anti-inflammatory analgesic antipyretic oxazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH512505A true CH512505A (en) | 1971-09-15 |
Family
ID=27177025
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH416070A CH526574A (en) | 1965-10-23 | 1967-09-29 | Process for the preparation of oxazolylalkanecarboxamides |
| CH275370A CH535250A (en) | 1965-10-23 | 1967-09-29 | Process for the preparation of esters of oxazolyl-alkanoic acids |
| CH83871A CH512505A (en) | 1965-10-23 | 1967-09-29 | Anti-inflammatory analgesic antipyretic oxazole |
| CH275470A CH535251A (en) | 1965-10-23 | 1967-09-29 | Alkylation process for the production of oxazole derivatives |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH416070A CH526574A (en) | 1965-10-23 | 1967-09-29 | Process for the preparation of oxazolylalkanecarboxamides |
| CH275370A CH535250A (en) | 1965-10-23 | 1967-09-29 | Process for the preparation of esters of oxazolyl-alkanoic acids |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH275470A CH535251A (en) | 1965-10-23 | 1967-09-29 | Alkylation process for the production of oxazole derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CH (4) | CH526574A (en) |
-
1967
- 1967-09-29 CH CH416070A patent/CH526574A/en not_active IP Right Cessation
- 1967-09-29 CH CH275370A patent/CH535250A/en not_active IP Right Cessation
- 1967-09-29 CH CH83871A patent/CH512505A/en not_active IP Right Cessation
- 1967-09-29 CH CH275470A patent/CH535251A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH535250A (en) | 1973-03-31 |
| CH526574A (en) | 1972-08-15 |
| CH535251A (en) | 1973-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1668648A1 (en) | New 3-benzoylphenyl acetic acid derivatives and their production | |
| CH507974A (en) | Anti-inflammatory analgesic antipyretic oxazole | |
| DE2201889A1 (en) | ARYLPIPERAZINE AND THE PROCESS FOR THEIR PRODUCTION | |
| DE569726C (en) | Process for the preparation of bis (halo-oxyaryl) oxides | |
| DE1815802A1 (en) | Process for the production of substituted phenylacetic acids | |
| CH626349A5 (en) | ||
| CH512505A (en) | Anti-inflammatory analgesic antipyretic oxazole | |
| DE2406881A1 (en) | NEW CARBONIC ACID DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
| EP1007507B1 (en) | Process for preparing 2-cyanoindan-1-ones | |
| DE1695633A1 (en) | Process for the preparation of new phenoxazine derivatives | |
| DE3212485A1 (en) | METHOD FOR PRODUCING 4-HYDROXY-3- (HETEROCYCLOCARBAMOYL) -2H-1,2-BENZOTHIAZINE-1,1-DIOXIDES | |
| CH527209A (en) | Anti-inflammatory analgesic antipyretic oxazole | |
| DE2462025A1 (en) | BETA-(2,5-DI-LOWER-ALKOXYPHENYL)-ACRYLICNITRILES OR DERIVATIVES THEREOF WITH ADDITIONAL SUBSTITUENTS ON THE BENZENE RING AT THE 3,4, AND'OR 6-POSITIONS, AND METHODS OF MAKING SAME | |
| AT217470B (en) | Process for the preparation of new 3-alkyl- or 3-alkanoyl-10, 11-dihydro-5-dibenzo [b, f] azepines and 3-alkyl-5-dibenzo [b, f] azepines | |
| DE2265053A1 (en) | NEW DISUBSTITUTED XANTHONACARBONIC ACID AMIDE | |
| AT226700B (en) | Process for the preparation of new benzimidazole derivatives | |
| DE1795105A1 (en) | New process for the preparation of 5-hydroxy-5-phenyl-2,3-dihydro-5H-imidazo [2,1-a] isoindoles | |
| DE1445521C (en) | Process for the preparation of In dazol (3) carboxylic acids | |
| AT233016B (en) | Process for the preparation of new iminodibenzyl derivatives | |
| CH621550A5 (en) | ||
| AT265299B (en) | Process for the preparation of new 3-morpholinone or 3-morpholinethione derivatives | |
| AT284848B (en) | Process for the preparation of 3-substituted 1,2,3,4-tetrahydro- or 1,2-dihydro-quinoxalin-2-ones | |
| AT222637B (en) | Process for the preparation of new dibenzocycloheptane derivatives | |
| AT246132B (en) | Process for the preparation of new 4-nitro-pyrazolecarboxylic acids | |
| AT226223B (en) | Process for the production of new phenylalanine derivatives and their salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |